联合治疗在胆道恶性肿瘤转化治疗中的应用探讨

doi:10.3969/j.issn.1009-976X.2021.02.001

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (02): 133-137.DOI: 10.3969/j.issn.1009-976X.2021.02.001

• 专家笔谈 • 下一篇

联合治疗在胆道恶性肿瘤转化治疗中的应用探讨

于小鹏, 童焕军, 汤朝晖^*

上海交通大学医学院附属新华医院普外科,上海 200092

通讯作者: *汤朝晖,Email：tangzhaohui@yahoo.com
作者简介:汤朝晖,医学博士、主任医师、教授、硕士生导师
上海交通大学医学院附属新华医院普外科主任医师,美国芝加哥大学医学中心访问学者; 中国医师协会外科医师分会胆道外科医师委员会副主任委员兼秘书长,青年委员会主任委员,中华医学会外科学分会脾脏及门静脉高压症学组委员,白求恩公益基金会肝胆专业委员会主任委员,国家卫生健康委员会加速康复外科（ERAS）专家委员会、能力建设和继续教育外科学专家委员会委员,中国抗癌协会肝癌专家委员会委员,美国外科医师学会会员（FACS）,国际肝胆胰协会中国分会外科委员;
担任《中华肝脏外科手术学电子杂志》《中华消化外科杂志》《中华转移性肿瘤杂志》《上海医学》《中国普外基础与临床杂志》《腹部外科》及Hepatology（中文版）等杂志编委及通讯编委,Gastroenterology、Cancer Lett、 Surgical Endoscopy及《第二军医大学学报》《浙江大学学报（医学版）》特约审稿人
基金资助:
国家自然科学基金资助项目（81772521）; 上海交通大学医学院附属新华医院院级临床研究培育基金（17CSK06）; 上海交通大学医学院多中心临床研究（DLY201807）

Discussion on application of combination therapy in conversion therapy of biliary tract cancer

YU Xiao-peng, TONG Huan-jun, TANG Zhao-hui

Department of General Surgery, Shanghai Xinhua Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China

Online:2021-04-20 Published:2021-06-18
Contact: TANG Zhao-hui, tangzhaohui@yahoo.com

摘要/Abstract

摘要： 胆道恶性肿瘤起病隐匿、发展迅速,大多患者在发现时已丧失手术机会,预后较差,转化治疗可以达到使患者肿瘤缩小或降期而具备手术条件并完成根治性切除的目的。由于胆道恶性肿瘤极具异质性的特点,其发生发展过程是多因素多途径的结果,因此联合治疗是提升转化治疗成功率、改善预后的主要方向,随着对胆道恶性肿瘤发生发展机制认识的逐渐深入,个体化、精准化联合治疗将成为未来转化治疗的主要方向。

关键词: 胆道恶性肿瘤, 转化治疗, 联合治疗, 异质性, 个体化

Abstract: Biliary tract cancer has insidious onset and rapid development thus most patients have lost the opportunity of surgery when they are found, so the prognosis is poorer. Conversion therapy can achieve the goal of making the tumor shrink or reduce its stage, so that patients have conditions for surgery and complete radical resection. Due to the occurrence and development of biliary tract cancer with great heterogeneity is the result of multiple elements and paths, combination therapy is becoming the main direction to improve the success rate of translational therapy and the prognosis currently. With the deepening understanding of the pathogenesis and development of biliary tract cancer, individualized and precise combination therapy will become the main direction of conversion therapy in the future.

Key words: biliary tract cancer（BTC）, conversion therapy, combination therapy, heterogeneity, individualization

中图分类号:

R735.8

于小鹏, 童焕军, 汤朝晖. 联合治疗在胆道恶性肿瘤转化治疗中的应用探讨[J]. 岭南现代临床外科, 2021, 21(02): 133-137.

YU Xiao-peng, TONG Huan-jun, TANG Zhao-hui. Discussion on application of combination therapy in conversion therapy of biliary tract cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 133-137.

参考文献

[1] Okusaka T, Nakachi K, Fukutomi A, et al.Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J]. Br J Cancer, 2010, 103(4): 469-474.
[2] Valle J, Wasan H, Palmer DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.
[3] Capussotti L, Muratore A, Mulas MM, et al.Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases[J]. Br J Surg, 2006, 93(8): 1001-1006.
[4] 何霞飞, 周永宁, 关泉林. Ⅳ期胃癌转化治疗现状[J]. 肿瘤药学, 2020, 10(2): 139-47,65.
[5] 汤朝晖, 于小鹏, 童焕军, 等. 从异质性角度看胆道恶性肿瘤的转化治疗[J]. 中华外科杂志, 2021, 59(4): 260-264.
[6] Shiina T, Mikuriya S, Uno T, et al.Radiotherapy of cholangiocarcinoma: the roles for primary and adjuvant therapies[J]. Cancer Chemother Pharmacol, 1992, 31(Suppl): S115-S118.
[7] Fukuda S, Okuda K, Kinoshita H, et al.Study of hepatic arterial chemoinfusion with continuous CDDP, 5-FU low dose administration for advanced gallbladder cancer[J]. Gan To Kagaku Ryoho, 1996, 23(11): 1610-1613.
[8] Hasegawa H, Ueo H, Nanbara S, et al.An effective pre-operative chemoimmunotherapy regimen against advanced gallbladder carcinoma: a case report[J]. Hepatogastroenterology, 1999, 46(27): 1639-1642.
[9] Bismuth H, Adam R, Lévi F, et al.Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy[J]. Annals of surgery, 1996, 224(4):509-520.
[10] Vogl TJ, Balzer JO, Dette K, et al.Initially unresectable hilar cholangiocarcinoma: hepatic regeneration after transarterial embolization[J]. Radiology, 1998, 208(1): 217-222.
[11] Kato A, Shimizu H, Ohtsuka M, et al.Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery[J]. Ann Surg Oncol, 2015, 22(Suppl 3): S1093-S1099.
[12] Riby D, Mazzotta AD, Bergeat D, et al.Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma[J]. Ann Surg Oncol, 2020, 27(10): 3729-3737.
[13] Abou-Alfa G K, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J]. Lancet Oncol, 2020, 21(5): 671-684.
[14] Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma[J]. Br J Cancer, 2019, 120(2): 165-171.
[15] Goyal L, Shi L, Liu LY, et al.TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma[J]. Cancer Discov, 2019, 9(8): 1064-1079.
[16] Abou-Alfa GK, Macarulla T, Javle MM, et al.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807.
[17] Bahleda R, Meric-Bernstam F, Goyal L, et al.Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors[J]. Ann Oncol, 2020, 31(10): 1405-1412.
[18] Lee SH, Lee HS, Lee SH, et al.Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study[J]. J Clin Med, 2020, 9(6): 1769.
[19] 于小鹏,童焕军,汤朝晖. 术前影像学检查联合临床实验室指标在肝内胆管癌术前诊断分型中价值的探讨[J]. 临床外科杂志, 2020, 28(8): 707-710.
[20] Zou S, Li J, Zhou H, et al.Mutational landscape of intrahepatic cholangiocarcinoma[J]. Nat Commun, 2014, 5: 5696.
[21] Sumiyoshi T, Shima Y, Okabayashi T, et al.Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma[J]. World J Surg, 2018, 42(9): 2910-2918.
[22] Fruscione M, Pickens RC, Baker EH, et al.Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review[J]. Curr Probl Cancer, 2021, 45(1): 100614.
[23] Halfdanarson TR, Foster NR, Kim GP, et al.A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)[J]. Oncologist, 2019, 24(5): 589-e160.
[24] Prieto M, Gastaca M, Ruiz P, et al.Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection[J]. Ann Hepatobiliary Pancreat Surg, 2019, 23(4): 403-407.
[25] Jeong H, Jeong JH, Kim KP, et al.Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin[J]. Cancers (Basel), 2021, 13(2): 161.
[26] Javle M, Churi C, Kang HC, et al.HER2/neu-directed therapy for biliary tract cancer[J]. J Hematol Oncol, 2015, 8: 58.
[27] Wang Z, Jin Y, Guo Y, et al.Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid[J]. Cancers, 2021, 13(5):1179.

联合治疗在胆道恶性肿瘤转化治疗中的应用探讨

Discussion on application of combination therapy in conversion therapy of biliary tract cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

[1]	黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(1): 110-114.
[2]	付佳禄, 雷建军, 张东, 耿智敏. 胆囊癌新辅助治疗研究现状[J]. 岭南现代临床外科, 2021, 21(03): 257-264.
[3]	丁陈陈, 宋兴东, 张磊. 肝脏外科医生眼中的2021 ASCO[J]. 岭南现代临床外科, 2021, 21(03): 265-271.
[4]	梁群英, 吴悦欣, 邱海玫. 个体化营养护理对头颈部肿瘤放化疗患者的应用效果[J]. 岭南现代临床外科, 2020, 20(06): 821-824.
[5]	叶伟恒, 梁俊杰, 罗迦耀, 胡友主. 成人腹股沟疝外科治疗的个体化方案选择[J]. 岭南现代临床外科, 2020, 20(05): 650-653.
[6]	陆晓华，黄嘉宝，胡丹. 个体化电话随访对人工全膝关节置换术后康复和身心健康的影响[J]. 岭南现代临床外科, 2018, 18(05): 553-557.
[7]	胡志刚王捷. 精准医疗时代肝细胞肝癌诊疗策略[J]. 岭南现代临床外科, 2016, 16(01): 1-6.